Murali M Chakinala1, Daniel W Coyne2, Raymond L Benza3, Adaani E Frost4, Michael D McGoon5, Brian K Hartline6, Robert P Frantz7, Mona Selej6, Carol Zhao6, David R Mink8, Harrison W Farber9. 1. Pulmonary & Critical Care Division, Washington University School of Medicine, St. Louis, Missouri, USA. Electronic address: chakinalam@wustl.edu. 2. Renal Division, Washington University School of Medicine, St. Louis, Missouri, USA. 3. General Hospital, Cardiovascular Diseases Pittsburgh, Pennsylvania, USA. 4. Weill Cornell Medical College, Houston Methodist Hospital Lung Center, Houston, Texas, USA. 5. Division of Cardiovascular Disease (Emeritus), Mayo Clinic, Rochester, Minnesota, USA. 6. Actelion Pharmaceuticals US, Inc., South San Francisco, California, USA. 7. Mayo Pulmonary Hypertension Clinic, Rochester, Minnesota, USA. 8. ICON Clinical Research, San Francisco, California, USA. 9. The Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Renal dysfunction is associated with abnormal cardiopulmonary hemodynamics, in-hospital death and poor survival in patients with pulmonary arterial hypertension (PAH), and thus it may be a prognostic biomarker. In our analysis we assess the relationship between change in estimated glomerular filtration rate (eGFR) and outcomes in PAH patients in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL). METHODS: Overall 2,368 patients were classified into chronic kidney disease (CKD) stages based on baseline eGFR: normal or Stages 1 or 2 (n = 1,699); Stage 3a (n = 399); Stage 3b (n = 196); and Stages 4 or 5 (n = 74). We evaluated the relationship between baseline CKD stage and survival, as well as the composite end-point of survival and freedom from all-cause hospitalization. The relationships between change in eGFR at ≥1 year and these clinical end-points were also evaluated. RESULTS: Patients with a ≥10% decline in eGFR from baseline over ≥1 year had a significantly increased risk of death (hazard ratio 1.66; p < 0.0001) and the composite of all-cause hospitalization and death (hazard ratio 1.33; p = 0.002). This decline predicted survival independently of changes in 6-minute walk distance and functional class. However, a ≥10% increase in eGFR was not significantly associated with either end-point. CONCLUSION: In REVEAL, a ≥10% decline in eGFR over ≥1 year independently predicted poorer survival. Thus, eGFR may be a simple and economical biomarker in PAH.
BACKGROUND:Renal dysfunction is associated with abnormal cardiopulmonary hemodynamics, in-hospital death and poor survival in patients with pulmonary arterial hypertension (PAH), and thus it may be a prognostic biomarker. In our analysis we assess the relationship between change in estimated glomerular filtration rate (eGFR) and outcomes in PAH patients in the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL). METHODS: Overall 2,368 patients were classified into chronic kidney disease (CKD) stages based on baseline eGFR: normal or Stages 1 or 2 (n = 1,699); Stage 3a (n = 399); Stage 3b (n = 196); and Stages 4 or 5 (n = 74). We evaluated the relationship between baseline CKD stage and survival, as well as the composite end-point of survival and freedom from all-cause hospitalization. The relationships between change in eGFR at ≥1 year and these clinical end-points were also evaluated. RESULTS:Patients with a ≥10% decline in eGFR from baseline over ≥1 year had a significantly increased risk of death (hazard ratio 1.66; p < 0.0001) and the composite of all-cause hospitalization and death (hazard ratio 1.33; p = 0.002). This decline predicted survival independently of changes in 6-minute walk distance and functional class. However, a ≥10% increase in eGFR was not significantly associated with either end-point. CONCLUSION: In REVEAL, a ≥10% decline in eGFR over ≥1 year independently predicted poorer survival. Thus, eGFR may be a simple and economical biomarker in PAH.
Authors: Lorriana E Leard; Are M Holm; Maryam Valapour; Allan R Glanville; Sandeep Attawar; Meghan Aversa; Silvia V Campos; Lillian M Christon; Marcelo Cypel; Göran Dellgren; Matthew G Hartwig; Siddhartha G Kapnadak; Nicholas A Kolaitis; Robert M Kotloff; Caroline M Patterson; Oksana A Shlobin; Patrick J Smith; Amparo Solé; Melinda Solomon; David Weill; Marlies S Wijsenbeek; Brigitte W M Willemse; Selim M Arcasoy; Kathleen J Ramos Journal: J Heart Lung Transplant Date: 2021-07-24 Impact factor: 13.569
Authors: Mario Naranjo; Valentina Mercurio; Hussein Hassan; Noura Alturaif; Alessandra Cuomo; Umberto Attanasio; Nermin Diab; Sarina K Sahetya; Monica Mukherjee; Steven Hsu; Aparna Balasubramanian; Catherine E Simpson; Rachel Damico; Todd M Kolb; Stephen C Mathai; Paul M Hassoun Journal: ERJ Open Res Date: 2022-05-16
Authors: Zongye Cai; Siyu Tian; Theo Klein; Ly Tu; Laurie W Geenen; Thomas Koudstaal; Annemien E van den Bosch; Yolanda B de Rijke; Irwin K M Reiss; Eric Boersma; Claude van der Ley; Martijn Van Faassen; Ido Kema; Dirk J Duncker; Karin A Boomars; Karin Tran-Lundmark; Christophe Guignabert; Daphne Merkus Journal: Sci Rep Date: 2022-07-19 Impact factor: 4.996
Authors: Bradley A Maron; Steven H Abman; C Greg Elliott; Robert P Frantz; Rachel K Hopper; Evelyn M Horn; Mark R Nicolls; Oksana A Shlobin; Sanjiv J Shah; Gabor Kovacs; Horst Olschewski; Erika B Rosenzweig Journal: Am J Respir Crit Care Med Date: 2021-06-15 Impact factor: 30.528
Authors: Nazzareno Galiè; Richard N Channick; Robert P Frantz; Ekkehard Grünig; Zhi Cheng Jing; Olga Moiseeva; Ioana R Preston; Tomas Pulido; Zeenat Safdar; Yuichi Tamura; Vallerie V McLaughlin Journal: Eur Respir J Date: 2019-01-24 Impact factor: 16.671